President Trump and Pfizer CEO Albert Bourla announced a major deal that will see the drug manufacturer commit to a $70 billion investment in America and reduce drug costs for users.

“In addition, Pfizer has agreed to provide some of their most popular current medications to all consumers at heavily discounted prices,” President Trump said.

“We’re also announcing that moving forward, all new medications introduced by Pfizer to the American market will be sold at the ‘most favored nation’ cost, so we’ll be paying essentially what other countries are paying,” the president added.

The $70 billion investment also will see drug manufacturing moved back to America.

“They’re going to bring a lot of their facilities to make their drugs…they’re going to make it in the United States. I appreciate that,” Trump said.

“We’re working with other major pharmaceutical companies to secure similar agreements,” the president said.

“By taking this bold step, we are ending the era of global price gouging at the expense of American families,” President Trump said.

This is part of his ‘Make America Healthy Again’ initiative.

In addition, President Trump said America is done subsidizing healthcare for the rest of the world.

“I can’t tell you how big this is,” President Trump said.

Pfizer CEO Albert Bourla called it a “historic day.”

“As a result, Americans had to assume disproportional costs on their shoulders. This situation we all knew is not sustainable,” Bourla said.

“This is changing today, with this agreement,” Bourla said.

Bourla said the deal satisfied all of President Trump’s requests.

“They [American patients] are the ones that will see significant impact in their ability to buy medicines,” Bourla said.

As the president mentioned earlier, other drug companies will be working with the administration.

President Trump called Bourla a “leader” and added the tariffs will be “an extra five, six, seven, eight percent.”

For years, countries with socialized healthcare systems have relied on American medical innovation and drug manufacturing.

Their healthcare systems do not have the funds to support such research and development.

As the president said, “The United States is done subsidizing the healthcare of the rest of the world.”

This deal represents a fundamental shift in how pharmaceutical pricing works in America.

The most favored nation pricing means Americans will pay what other countries pay.

This ends the practice of foreign nations getting discounts while Americans pay premium prices.

The $70 billion investment will create thousands of American manufacturing jobs.

Bringing drug production back to America strengthens national security and supply chain independence.

During the pandemic, America learned the danger of relying on foreign pharmaceutical manufacturing.

Trump’s deal ensures critical medications will be made domestically.

The heavily discounted prices on popular medications will provide immediate relief to American families.

Prescription drug costs have been crushing middle-class budgets for decades.

This agreement shows Trump’s negotiating skills in action with major corporations.

Bourla’s acknowledgment that Americans carried “disproportional costs” validates Trump’s criticism of the old system.

The CEO admitted the previous situation was unsustainable and unfair to American patients.

Trump’s tariff strategy gives him leverage to secure deals like this.

The additional five to eight percent tariff threat encourages compliance from pharmaceutical companies.

Other drug manufacturers are now negotiating similar agreements with the administration.

This could trigger an industry-wide transformation in how medications are priced.

Foreign countries have gotten cheap drugs by free-riding on American innovation for too long.

Americans funded the research and development through high prices while others benefited.

Trump is correcting this unfair arrangement that hurt American families.

The Make America Healthy Again initiative combines healthcare access with manufacturing revival.

This deal advances both goals simultaneously through one historic agreement.

Bourla’s cooperation shows pharmaceutical executives recognize the political winds have shifted.

They can either work with Trump or face the consequences of his tariff policies.

The president’s America First approach extends to healthcare and prescription drugs.

This agreement proves Trump delivers on his campaign promises to lower drug costs.

Previous administrations talked about fixing pharmaceutical pricing but accomplished little.

Trump actually secured concrete commitments with measurable results for Americans.

The immediate discount on popular medications means families will see savings quickly.

This isn’t a future promise but a present-day solution to high drug costs.